Statins to reduce renal sinus fat among breast cancer patients undergoing anthracycline-based chemotherapy: A substudy of PREVENT-WF-98213
Open Access
- 16 September 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0318017
Abstract
Objective: To test if statin administration attenuated renal sinus fat (RSF) accumulation and if RSF was associated with renal function in women with breast cancer (BC) receiving anthracycline-based chemotherapy. Methods: This was a secondary analysis in a subgroup of women with stage I-III BC randomized to placebo (n = 35) or statin (40 mg/day atorvastatin, n = 44) therapy. At baseline and 24-months after randomization, RSF and intraabdominal fat were measured from magnetic resonance images, and estimated glomerular filtration rate (eGFR) was calculated from serum creatinine. Results: Participants in this study averaged 51 years of age (SD 11), 87% reported White race, and had a mean BMI (±SD) of 30.2 kg/m2 (±6.1). Most participants (60%) were diagnosed with stage II BC. At 24-months, RSF was higher in the placebo group relative to the statin group (β [95% CI], p-value: 0.17 [0.009, 0.34], p = 0.04). After adjusting for baseline RSF, this signal remained but was attenuated (β [95% CI], p-value: 0.12 [−0.06, 0.29], p = 0.18). In all participants at baseline and prior to beginning chemotherapy for BC or study drug, higher RSF was associated with lower eGFR values in all participants (r = −0.23, p = 0.03). At 24-months by study group, greater RSF was associated with decreased eGFR in the placebo group (−0.51, p = 0.01) but not in the statin group (−0.25, p = 0.19). Discussion: Statin administration may lower RSF during anthracycline-based chemotherapy. These findings merit further investigation to determine if statins protect renal function during BC treatment.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01HL118740)
- National Institutes of Health (T32CA093423)
- National Institutes of Health (UG1CA189824)
- National Institutes of Health (UG1CA189828)
- National Institutes of Health (UG1CA189823)
- Susan G. Komen (CTA241184399)
- National Heart, Lung, and Blood Institute (K99HL173554)
- American Heart Association (23SFRNPCS1063854)
- American Heart Association (23SFRNPCS1063854)
- American Heart Association (23SFRNPCS1063854)
- National Heart, Lung, and Blood Institute (R01HL118740)
- National Institutes of Health (UG1CA189824)
- National Institutes of Health (UG1CA189824)
This publication has 30 references indexed in Scilit:
- Intermuscular Fat Changes Are Related to Reduced Left Ventricular Ejection Fraction During Cancer Therapy (PREVENT-WF-98213)JACC: Cardiooncology, 2023
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney DiseaseAmerican Journal of Kidney Diseases, 2022
- Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapyBreast Cancer Research and Treatment, 2021
- Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysisScientific Reports, 2019
- Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statementThe Lancet Diabetes & Endocrinology, 2019
- Renal sinus fat and renal hemodynamics: a cross-sectional analysisMagnetic Resonance Materials in Physics, Biology and Medicine, 2019
- Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissueInternational Journal of Cardiology, 2019
- Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline ChemotherapyJACC, 2012
- Obesity and Hypertension: Mechanisms, Cardio-Renal Consequences, and Therapeutic ApproachesMedical Clinics of North America, 2009
- Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug managementCancer, 2007